Estudo da encapsulação do Haloperidol em sílica mesoporosa SBA-15 e de sua liberação in vitro e, preliminarmente, in vivo em um modelo animal de esquizofrenia
Arquivos
Data
2012
Autores
Salles Júnior, Cláudio Gomes 
Orientadores
Mercuri, Lucildes Pita
Tipo
Dissertação de mestrado
Título da Revista
ISSN da Revista
Título de Volume
Resumo
A sílica mesoporosa SBA-15 possui altos volumes de poro e área superficial, além de estabilidade térmica, hidrotérmica e mecânica [1,6] o que a torna viável como veiculo capaz de carrear substâncias de natureza distintas como o antipsicótico haloperidol, que é muito utilizado na psiquiatria clinica para o tratamento de transtornos psicóticos, destacando em especial o tratamento dos sintomas positivos da esquizofrenia. Dessa forma, o objetivo principal desse trabalho foi estudar a encapsulação do fármaco haloperidol na sílica mesoporosa SBA-15, utilizando para tanto diversas técnicas de caracterização física, físico-químicas e analíticas, tais como: Microscopia Eletrônica de Varredura (MEV), Adsorção de Nitrogênio, Termogravimetria/Termogravimetria Derivada (TG/DTG), Calorimetria Exploratória Diferencial (DSC), Análise Elementar (AE) e Cromatografia em fase líquida de alta eficiência (CLAE). E, acompanhar, também, o comportamento de liberação controlada in vitro desse fármaco após sua encapsulação na SBA-15, assim como, avaliar, preliminarmente, sua liberação in vivo utilizando um modelo de esquizofrenia induzido em ratos. Inicialmente, os resultados obtidos mostraram que a SBA-15 apresentou uma boa capacidade de encapsulação desse fármaco alcançando até 60% do ativo na nanomatriz, além de um perfil de liberação in vitro, do material SBA-15/haloperidol diferenciado do fármaco na forma pura. Com isso, pode-se avaliar, preliminarmente, que seu efeito em modelo animal de esquizofrenia apresentou diferenças significativas de comportamento, ou seja, observou que a ocorrência da reversão do efeito de indução da esquizofrenia foi mais acentuada no pré-tratamento com a nova formulação, SBA-15/fármaco, em relação ao pré-tratamento com o fármaco puro
The mesoporous silica SBA-15 has high pore volumes and surface area, and thermal stability, hydrothermal and mechanical [1.6] which makes it feasible as a vehicle capable of carrying distinct substances such as antipsychotic haloperidol, which is much used in clinical psychiatry to treat psychotic disorders, highlighting in particular the treatment of positive symptoms of schizophrenia. Thus, the main objective of this work was to study the encapsulation of the drug haloperidol on mesoporous silica SBA-15 using various techniques for both physical, physicalchemical and analytical, such as Scanning Electron Microscopy (SEM), adsorption nitrogen, Thermogravimetry/Derivative Thermogravimetry (TG / DTG), Differential Scanning Calorimetry (DSC), Elemental Analysis (EA) and chromatography high performance liquid (HPLC). And follow also the behavior of in vitro controlled release of the drug after its encapsulation in SBA-15, as well as assess, preliminarily, its release in vivo using a model of schizophrenia induced in mice. Initially, the results showed that the SBA-15 showed a good ability to encapsulation of the drug reaching up to 60% of assets in nanomatriz, and a release profile in vitro, differentiated material SBA-15/haloperidol the drug in pure form. Thus, one can evaluate preliminarily its effect in an animal model of schizophrenia significant differences in behavior, noted that the occurrence of reversion-inducing effect of schizophrenia was more pronounced in the pre-treatment with the new formulation, SBA-15/haloperidol and compared to pretreatment with pure drug, especially in higher doses.
The mesoporous silica SBA-15 has high pore volumes and surface area, and thermal stability, hydrothermal and mechanical [1.6] which makes it feasible as a vehicle capable of carrying distinct substances such as antipsychotic haloperidol, which is much used in clinical psychiatry to treat psychotic disorders, highlighting in particular the treatment of positive symptoms of schizophrenia. Thus, the main objective of this work was to study the encapsulation of the drug haloperidol on mesoporous silica SBA-15 using various techniques for both physical, physicalchemical and analytical, such as Scanning Electron Microscopy (SEM), adsorption nitrogen, Thermogravimetry/Derivative Thermogravimetry (TG / DTG), Differential Scanning Calorimetry (DSC), Elemental Analysis (EA) and chromatography high performance liquid (HPLC). And follow also the behavior of in vitro controlled release of the drug after its encapsulation in SBA-15, as well as assess, preliminarily, its release in vivo using a model of schizophrenia induced in mice. Initially, the results showed that the SBA-15 showed a good ability to encapsulation of the drug reaching up to 60% of assets in nanomatriz, and a release profile in vitro, differentiated material SBA-15/haloperidol the drug in pure form. Thus, one can evaluate preliminarily its effect in an animal model of schizophrenia significant differences in behavior, noted that the occurrence of reversion-inducing effect of schizophrenia was more pronounced in the pre-treatment with the new formulation, SBA-15/haloperidol and compared to pretreatment with pure drug, especially in higher doses.